

# **ATMEKSI- methocarbamol suspension**

## **Metacel Pharmaceuticals, LLC**

-----

### **HIGHLIGHTS OF PRESCRIBING INFORMATION**

**These highlights do not include all the information needed to use ATMEKSI® (methocarbamol) oral suspension safely and effectively. See full prescribing information for ATMEKSI (methocarbamol) oral suspension.**

### **ATMEKSI (methocarbamol) oral suspension**

**Initial U.S. Approval: 05/07/2018**

### **INDICATIONS AND USAGE**

**ATMEKSI (methocarbamol) oral suspension** is a muscle relaxant indicated as:

- an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients 16 and older.

### **DOSAGE AND ADMINISTRATION**

- Adults

Initial dosage: 1,500 mg (10 mL) 4 times daily

Maintenance dosage: 750 mg (5 mL) every 4 hours or 1,500 mg (10 mL) 3 times daily

Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

### **DOSAGE FORMS AND STRENGTHS**

- oral suspension: 750 mg/5 mL

### **CONTRAINDICATIONS**

Hypersensitivity to ATMEKSI or any component in the product ( 4.1)

### **WARNINGS AND PRECAUTIONS**

- ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol ( 5.1)
- ATMEKSI may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle ( 5.2)

### **ADVERSE REACTIONS**

- *Body*: Anaphylactic reaction, angioneurotic edema, fever, headache ( 6)
- *Cardiovascular system*: Bradycardia, flushing, hypotension, syncope, thrombophlebitis ( 6)
- *Digestive system*: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting ( 6)
- *Hemic and lymphatic system*: Leukopenia ( 6)
- *Immune system*: Hypersensitivity reactions ( 6)
- *Nervous system*: Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo ( 6)
- *Skin and special senses*: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash and urticaria ( 6)

**To report SUSPECTED ADVERSE REACTIONS, contact Rosemont Pharmaceuticals, LLC. at 1-844-638-2235 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch) .**

### **DRUG INTERACTIONS**

- ATMEKSI may inhibit the effect of pyridostigmine bromide. Patients with myasthenia gravis should be monitored closely for symptoms of myasthenia gravis such as weakness. If symptoms of myasthenia gravis are observed, treatment with ATMEKSI should be stopped immediately ( 7.2)
- Laboratory test interference: Methocarbamol may cause color interference in the following screening tests: 5-hydroxyindoleacetic acid (using nitrosonaphthol reagent) and VMA (Giltow method) ( 7.3)

### **USE IN SPECIFIC POPULATIONS**

**Lactation:** The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ATMEKSI and any potential adverse effects on the breastfed infant from methocarbamol or the underlying maternal condition .

---

## **FULL PRESCRIBING INFORMATION: CONTENTS\***

### **1 INDICATIONS AND USAGE**

- 1.1 Acute, painful musculoskeletal conditions.

### **2 DOSAGE AND ADMINISTRATION**

- 2.1 Important Dosage and Administration Instructions

### **3 DOSAGE FORMS AND STRENGTHS**

### **4 CONTRAINDICATIONS**

- 4.1 Hypersensitivity

### **5 WARNINGS AND PRECAUTIONS**

- 5.1 CNS Depressants and Alcohol Use
- 5.2 Use in Activities Requiring Mental Alertness

### **6 ADVERSE REACTIONS**

### **7 DRUG INTERACTIONS**

- 7.1 CNS drugs and alcohol
- 7.2 Pyridostigmine Bromide
- 7.3 Drug/Laboratory Test Interactions

### **8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use

### **10 OVERDOSAGE**

### **11 DESCRIPTION**

### **12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics

### **13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### **16 HOW SUPPLIED/STORAGE AND HANDLING**

- 16.1 How Supplied
- 16.2 Storage and Handling

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

#### **1.1 Acute, painful musculoskeletal conditions.**

ATMEKSI is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients

16 and older.

## **2 DOSAGE AND ADMINISTRATION**

### **2.1 Important Dosage and Administration Instructions**

Initial dosage: 1,500 mg (10 mL) 4 times daily

Maintenance dosage: 750 mg (5 mL) every 4 hours or 1,500 mg (10 mL) 3 times daily

Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

Inform the patient to shake the drug product for at least 30 seconds to ensure it is uniform before administration.

## **3 DOSAGE FORMS AND STRENGTHS**

Oral Suspension: 750 mg/5 mL of methocarbamol as a white to off-white suspension with a fruit flavor

## **4 CONTRAINDICATIONS**

### **4.1 Hypersensitivity**

ATMEKSI is contraindicated in patients hypersensitive to methocarbamol or to any of the oral suspension components.

## **5 WARNINGS AND PRECAUTIONS**

### **5.1 CNS Depressants and Alcohol Use**

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see *Drug Interactions* (7.1)].

### **5.2 Use in Activities Requiring Mental Alertness**

ATMEKSI may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

## **6 ADVERSE REACTIONS**

The following serious adverse reaction is described elsewhere in the labeling:

- Interactions with CNS Depressants and Alcohol [ see *Warnings and Precautions (5.1)*]

The following adverse reactions associated with the use of methocarbamol have been identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Adverse reactions reported with the administration of methocarbamol include:

Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache.

Cardiovascular system:Bradycardia, flushing, hypotension, syncope, thrombophlebitis.

Digestive system:Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting.

Hemic and lymphatic system:Leukopenia.

Immune System:Hypersensitivity reactions.

Nervous system:Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo.

Skin and special senses:Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria.

## **7 DRUG INTERACTIONS**

### **7.1 CNS drugs and alcohol**

ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol [ see *Warnings and Precautions (5.1)*].

### **7.2 Pyridostigmine Bromide**

ATMEKSI may inhibit the effect of pyridostigmine bromide. Patients with myasthenia gravis should be monitored closely for symptoms of myasthenia gravis such as weakness. If symptoms of myasthenia gravis are observed, treatment with ATMEKSI should be stopped immediately.

### **7.3 Drug/Laboratory Test Interactions**

ATMEKSI may cause color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

#### Risk Summary

Limited data from case reports over decades of use with methocarbamol during pregnancy have not identified an increased risk of major birth defects, miscarriage or

other adverse maternal or fetal outcomes.

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized patients is 2 to 4% and 15 to 20% respectively.

## **8.2 Lactation**

### Risk Summary

There are no data on the presence of methocarbamol or its metabolites in human milk, the effects on a breastfed infant or the effects on milk production. Methocarbamol and/or its metabolite are present in animal milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ATMEKSI and any potential adverse effects on the breastfed infant from ATMEKSI or the underlying maternal condition.

## **8.4 Pediatric Use**

Safety and effectiveness of methocarbamol oral suspension in pediatric patients below the age of 16 have not been established.

## **10 OVERDOSAGE**

### Clinical Presentation

Deaths have been reported with an overdose of methocarbamol alone and when methocarbamol was used with other CNS depressants, including alcohol. Limited information is available on the acute toxicity of methocarbamol. Symptoms of overdose include the following: respiratory depression, nausea, drowsiness, blurred vision, hypotension, seizures, coma, and death. Other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants) can have an additive effect, even when taken at recommended dosages.

### Treatment of Overdose

The standard of treatment is supportive care, including monitoring for CNS and respiratory depression and managing airway as needed, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary.

Hypotension should be treated with intravenous fluids and vasopressors as needed. Gastrointestinal decontamination procedures (including emesis) should generally be avoided because aspiration may result from CNS depression and seizures.


Extracorporeal elimination such as hemodialysis or plasmapheresis has no proven clinical benefit. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

## **11 DESCRIPTION**

ATMEKSI (methocarbamol) Oral Suspension is a central nervous system (CNS)

depressant with sedative and musculoskeletal relaxant properties.

The chemical name of methocarbamol is ( $\pm$ )-1,2-Propanediol, 3-(2-methoxyphenoxy)-, 1-carbamate, or ( $\pm$ )-3-(*o*-Methoxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C<sub>11</sub>H<sub>15</sub>NO<sub>5</sub>. Its molecular weight is 241.24g/mol. The structural formula is shown below:



Methocarbamol is a white powder, sparingly soluble in water and in chloroform, soluble in alcohol (only with heating), insoluble in benzene and in *n*-hexane.

ATMEKSI (methocarbamol) Oral Suspension is a white to off-white suspension with a fruit flavor and a pH range of 3.2 – 4.8.

ATMEKSI (methocarbamol) Oral Suspension contains the following inactive ingredients: citric acid monohydrate, glycerin, magnesium aluminum silicate, purified water, sodium benzoate, sodium carboxymethylcellulose, sodium citrate, sucralose and fruit flavor.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

The mechanism of action of methocarbamol in humans has not been established but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate, or the nerve fiber.

### 12.3 Pharmacokinetics

#### Absorption

After oral administration in healthy volunteers, ATMEKSI is rapidly absorbed with a median T<sub>max</sub> of 0.66 hours. Food decreases the extent and delays the rate of absorption of methocarbamol. In the presence of food, the C<sub>max</sub> is decreased by 51% and the AUC is decreased by 31%. The median T<sub>max</sub> is delayed to 1.6 hours.

#### Distribution

Methocarbamol demonstrates moderate binding to plasma proteins, typically ranging from 46% to 50%.

#### Elimination

In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg. The mean plasma elimination half-life of ATMEKSI in healthy volunteers is approximately 1.3 hours and 1.5 hours when administered with or without food.

#### Metabolism

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of

methocarbamol also is likely. Essentially all methocarbamol metabolites are eliminated in the urine.

#### *Excretion*

Small amounts of unchanged methocarbamol also are excreted in the urine.

#### Specific Populations

##### *Geriatric Patients*

The mean ( $\pm$  SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean ( $\pm$  SD) age, 69 ( $\pm$  4) years) was slightly prolonged compared to a younger (mean ( $\pm$  SD) age, 53.3 ( $\pm$  8.8) years), healthy population (1.5 ( $\pm$  0.4) hours versus 1.1 ( $\pm$  0.27) hours, respectively). The fraction of bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41 to 43% versus 46 to 50%, respectively).

##### *Pediatric Patients*

Safety and effectiveness of methocarbamol oral suspension in pediatric patients below the age of 16 have not been established.

##### *Patients with Renal Impairment*

The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean ( $\pm$  SD) elimination half-life in these two groups was similar: 1.2 ( $\pm$  0.6) versus 1.1 ( $\pm$  0.3) hours, respectively.

##### *Patients with Hepatic Impairment*

In 8 patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to that obtained in 8 age- and weight-matched normal subjects. The mean ( $\pm$  SD) elimination half-life in the cirrhotic patients and the normal subjects was 3.38 ( $\pm$  1.62) hours and 1.11 ( $\pm$  0.27) hours, respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% compared to 46 to 50% in the normal subjects.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

#### Carcinogenesis

Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed.

#### Mutagenesis

No studies have been conducted to assess the effect of methocarbamol on mutagenesis.

#### Impairment of Fertility

No studies have been conducted to assess the effect of methocarbamol on its potential to impair fertility.

## **16 HOW SUPPLIED/STORAGE AND HANDLING**

### **16.1 How Supplied**

ATMEKSI (methocarbamol) Oral Suspension contains 750 mg/5 mL methocarbamol. It is a white to off-white suspension with a fruit flavor and is supplied in bottles of 150 mL with a child-resistant closure (NDC 69528-701-05).

### **16.2 Storage and Handling**

Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Keep out of reach and sight of children.

## **17 PATIENT COUNSELING INFORMATION**

- Caution patients that ATMEKSI may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
- Because ATMEKSI may possess a general CNS-depressant effect, caution patients about combined effects with alcohol and other CNS depressants.

### **Manufactured for:**

Rosemont Pharmaceuticals, LLC

Greenville, SC 29615

[www.rosemontpharmaceuticals.com](http://www.rosemontpharmaceuticals.com)

ATMEKSI<sup>®</sup> is a registered trademark of Rosemont Pharmaceuticals Ltd.

PI-MET-01-001

### **Principal Display Panel - 150 mL Bottle**

NDC 69528-701-05

Atmeksi

(methocarbamol)

Oral Suspension

750 mg/5 mL

150 mL




NDC 69528-701-05

Rx only

**ATMEKSI<sup>®</sup>**  
(methocarbamol)  
Oral Suspension

750 mg/5 mL

150 mL



Each 5 mL contains 750 mg of methocarbamol.

**Recommended Dosage:**  
See prescribing information.

Store and dispense in the original packaging.

Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].

Shake the medicine for at least 30 seconds to ensure a uniform suspension before administering.

**Keep out of reach and sight of children.**


Lot: #####

EXP: YYYY-MM-DD

**Manufactured for:**  
Rosemont Pharmaceuticals, LLC  
Greenville, SC 29615  
[www.rosemontpharmaceuticals.com](http://www.rosemontpharmaceuticals.com)

For more information, call (844) 638-2235

SP-LM-051 v.01  
Revised 08/2025

  
3 69528 70105 0

ATMEKSI

methocarbamol suspension

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:69528-701
Route of Administration	ORAL		
Active Ingredient/Active Moiety			
Ingredient Name		Basis of Strength	Strength
METHOCARBAMOL (UNII: 125OD7737X) (METHOCARBAMOL - UNII:125OD7737X)		METHOCARBAMOL	750 mg in 5 mL
Inactive Ingredients			
Ingredient Name			Strength
CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)			
SODIUM CITRATE (UNII: 1Q73Q2JULR)			
MAGNESIUM ALUMINUM SILICATE (UNII: 6M3P64V0NC)			
SODIUM BENZOATE (UNII: OJ245FE5EU)			
GLYCERIN (UNII: PDC6A3C0OX)			
SUCRALOSE (UNII: 96K6UQ3ZD4)			
CARBOXYMETHYLCELLULOSE SODIUM (UNII: K679OBS311)			
WATER (UNII: 059QF0KO0R)			
Product Characteristics			
Color		Score	
Shape		Size	
Flavor	FRUIT	Imprint Code	
Contains			

**Packaging**

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:69528-701-05	150 mL in 1 BOTTLE; Type 0: Not a Combination Product	01/15/2026	

**Marketing Information**

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA219843	12/22/2025	

**Labeler** - Metacel Pharmaceuticals, LLC (079475312)

Revised: 11/2025

Metacel Pharmaceuticals, LLC